Treatment of Recurrent Malignant Gliomas With Stereotactic Intensity Modulated Radiation TherapyVoynov, George M.D.; Kaufman, Seth M.D.; Hong, Theodore M.D.; Pinkerton, Arthur; Simon, Richard M.D.; Dowsett, Robert M.D.American Journal of Clinical Oncology: December 2002 - Volume 25 - Issue 6 - p 606-611 Article Abstract Author Information Malignant gliomas are usually refractory to aggressive combined-modality therapy, and the incidence of recurrence and death after treatment is very high. State-of-the-art techniques such as stereotactic intensity-modulated radiation therapy (IMRT) are now available to deliver a high dose of radiation to the tumor with relative preservation of surrounding tissues to achieve optimal tumor coverage with minimal toxicity. We report 10 patients (median age 48 years) with recurrent malignant gliomas that were treated with stereotactic directed IMRT. Initial tumor histologies included one low grade glioma (upgraded to anaplastic astrocytoma at recurrence), four anaplastic astrocytomas, and four glioblastomas multiforme. One patient was originally presumed to have a brain metastasis secondary to renal cell carcinoma but was pathologically confirmed as having glioblastoma multiforme at the time of recurrence. Before recurrence, all patients had been treated with external beam radiation therapy (median 59.7 Gy). All recurrences were confirmed by a subtotal resection (5/10) or by imaging (5/10). The median Karnofsky performance score at the time of IMRT was 80. The median tumor volume was 34.69 cm3. Treatment was delivered on a 10-MV linear accelerator with a mini-multileaf collimator, MIMiC, and planned with Peacock/Corvus software. Radiation was delivered in daily fractions of 5 Gy, to a total median dose of 30 Gy at the 71% to 93% median isodose line. Median overall survival time was 10.1 months from the date of stereotactic treatment, with 1- and 2-year survival rates of 50% and 33.3%, respectively. Fractionated stereotactic intensity modulated radiation therapy is a novel technique used in the treatment of recurrent malignant gliomas, which produces results comparable to other currently used stereotactic techniques. From Departments of Radiation Oncology (G.V., S.K., T.H., A.P., R.D.) and Neurosurgery (R.S.), University of Connecticut Health Center, Farmington, Connecticut, U.S.A. Address correspondence and reprint requests to Dr. Robert J. Dowsett, Department of Radiation Oncology, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030-2930, U.S.A. © 2002 Lippincott Williams & Wilkins, Inc.